Hostname: page-component-7479d7b7d-qlrfm Total loading time: 0 Render date: 2024-07-14T00:54:06.003Z Has data issue: false hasContentIssue false

Drug prescriptions associated with long acting. Pharmaco-economic aspects

Published online by Cambridge University Press:  23 March 2020

A. Riolo
Affiliation:
ASS 1 Triestina, Department of Mental Health, Trieste, Italy
F. Babici
Affiliation:
ASS 1 Triestina, Department of Mental Health, Trieste, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The polypharmacy is a very controversial subject; it brings together problems of interaction between drugs, side effects, and rationality of co-prescriptions, pharmaco-economic aspects. The long acting is useful to solve adherence to treatment but they are often prescribed in polytherapy.

Method

The aim of this studies is to compare long-acting haloperidol, fluphenazine, risperidone and paliperidone regard to prescribing associations and pharmaco-economy. Also we want to consider for each long-acting which and how many drugs are associated and the implications in terms of pharmaco-economics. We examined all prescriptions (126 patients) over a period of 12 months in a mental health center, identifying which long acting had the best pharmaco-economic profile.

Results

Despite being the less prescribed and not being associated with other psychiatric drugs, paliperidone palmitate shows the best pharmaco-economic profile.

Conclusions

The costs of a drug are in relationship not only with unit price but also with the question of safety in order to oppose the overmedication.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Viewing: Psychopharmacology and pharmacoeconomics
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.